NeuroPace, Inc.
NeuroPace, Inc. scores highest on Earnings (62) and lowest on Price (1). Its PosiPenta is 36.12 out of 100, weaker than most similar companies.
On the Penta Grid this week, NeuroPace, Inc. is Grid #642 of 837 in the Healthcare sector in United States, and Grid #3,206 of 4,000 in United States.
Compared with similar companies in the Healthcare sector in United States.
The five pillars
Similar companies
| Company | PosiPenta | P | E | N | T | A |
|---|---|---|---|---|---|---|
| NeuroPace, Inc. | 36.12 | 1 | 62 | 61 | 16 | 41 |
| Eikon Therapeutics, Inc. | 38.23 | 41 | 26 | 37 | 29 | 59 |
| MapLight Therapeutics, Inc. | 40.66 | 37 | 33 | 16 | 52 | 65 |
| Ovid Therapeutics Inc. | 52.31 | 29 | 40 | 71 | 60 | 62 |
| DiaMedica Therapeutics Inc. | 45.76 | 6 | 37 | 72 | 52 | 62 |
| Cerus Corporation | 46.44 | 11 | 74 | 64 | 43 | 40 |
Similar-sized companies in the same sector, this week. P Price · E Earnings · N Nitro · T Torque · A Anchor.
Details
PPrice
| P/E ratio | -21.47 |
| P/B ratio | 35.36 |
EEarnings
| Trailing EPS | ₹-53.99 |
| Forward EPS | ₹-20.60 |
NNitro
| Price | 1159.31 |
| 52-week high | 1856.41 |
| 52-week low | 873.27 |
| Fall from 52-week high | 37.6% |
TTorque
| Return on equity (ROE) | -103.27% |
| Debt-to-equity | 5.88 |
AAnchor
| Beta (price swings) | 1.87 |
| Market cap | ₹3,979 Cr |
| Insider holding | 4.46% |
| Dividend yield | 0.00% |
Figures as used for the week of 17 Oct 2026; today's figures on the company page may differ slightly.
Questions
What is NeuroPace, Inc.'s PosiPenta score?
NeuroPace, Inc.'s PosiPenta is 36.12 out of 100 for the week of 17 Oct 2026, based on 5 of 5 pillars.
Where does NeuroPace, Inc. stand on the Penta Grid?
On the Penta Grid this week, NeuroPace, Inc. is Grid #642 of 837 in the Healthcare sector in United States, and Grid #3,206 of 4,000 in United States.
Which PosiPenta pillar is strongest for NeuroPace, Inc.?
Earnings (growth), with a score of 62 out of 100: better than most similar companies.
Which PosiPenta pillar is weakest for NeuroPace, Inc.?
Price (valuation), with a score of 1 out of 100: much weaker than most similar companies.
Has NeuroPace, Inc.'s PosiPenta changed since last week?
Yes, it rose 3.50 points, from 32.62 to 36.12.
PositoAI is for research and education only and is not investment advice.